Edition:
India

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

78.00CHF
19 Jan 2018
Change (% chg)

CHF0.60 (+0.78%)
Prev Close
CHF77.40
Open
CHF77.45
Day's High
CHF78.25
Day's Low
CHF77.30
Volume
32,618
Avg. Vol
56,322
52-wk High
CHF95.35
52-wk Low
CHF70.10

Latest Key Developments (Source: Significant Developments)

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

MedCap unit to distribute Basilea's products in Scandinavia
Tuesday, 20 Sep 2016 

MedCap AB (publ) : Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd .Agreement is for distribution of Basilea's products in Sweden, Denmark, Norway and Finland.  Full Article

Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region
Wednesday, 17 Aug 2016 

Basilea Pharmaceutica AG :Basilea announces distribution agreement with Hikma for Cresemba (isavuconazole) in the MENA region.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 27.9 million
Monday, 15 Aug 2016 

Basilea Pharmaceutica AG : Contract revenue in first half-year of 2016 amounted to 27.8 million Swiss francs ($28.50 million) (H1 2015: 24.4 million francs) . In H1 2016, operating loss amounted to 24.8 million francs, compared to 30.0 million francs in H1 2015 . H1 2016 product revenue amounted to 1.9 million francs (H1 2015: 0 million francs) . Total operating income in H1 2016 including sales amounted to 29.7 million francs (H1 2015: 25.0 million francs) . H1 net loss amounted to 27.9 million francs (H1 2015: 30.1 million francs) .Confirms guidance for total operating expenses for 2016 of approximately 9 - 10 million francs on average per month and average operating loss in 2016 of approximately 4 - 5 million francs per month.  Full Article

Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy
Monday, 27 Jun 2016 

Basilea Pharmaceutica AG :Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy.  Full Article

Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833
Thursday, 21 Apr 2016 

Basilea Pharmaceutica AG:Reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting.Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment.PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models.  Full Article

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​